1. Signaling Pathways
  2. Immunology/Inflammation
  3. Fc Receptor (FcR)

Fc Receptor (FcR) (Fc 受体 (FcR))

Fc Receptor

Fc 受体 (FcR) 是一类能够识别并结合免疫球蛋白 Fc 段的细胞表面受体,在免疫应答和免疫调节等过程中发挥重要作用。按照识别的免疫球蛋白类型 Fc 受体可分为 FcγR、FcεR 和 FcαR 等。按照功能特性可分为激活型 Fc 受体和抑制型 Fc 受体。Fc 受体可介导免疫细胞的吞噬作用,促使吞噬细胞清除病原体等抗原性异物。Fc 受体也参与 ADCC,激活 NK 细胞等杀伤靶细胞,影响免疫应答。此外,Fc 受体可以清除免疫复合物,防止其在组织中沉积引发炎症。Fc 受体功能异常或表达的失调可引发自身免疫性疾病和过敏性疾病,在肿瘤中既涉及肿瘤细胞的免疫逃逸又可作为免疫治疗的作用靶点[1][2]

Fc Receptors (FcR) are a class of cell surface receptors that can recognize and bind to the Fc region of immunoglobulins, playing an important role in processes such as the immune response and immune regulation. According to the types of immunoglobulins they recognize, FcR can be classified into FcγR, FcεR, FcαR, etc. According to their functional characteristics, they can be divided into activating FcR and inhibitory FcR. FcR mediate the phagocytosis of immune cells, prompting phagocytes to eliminate antigenic foreign substances such as pathogens. FcR also participate in ADCC, which activates NK cells and other cells to kill target cells, affecting the immune response. In addition, FcR can clear immune complexes and prevent them from depositing in tissues and triggering inflammation. Abnormal functions or dysregulated expressions of FcR can lead to autoimmune diseases and allergic diseases. In tumors, FcR are involved in both the immune escape of tumor cells and can serve as targets for immunotherapy[1][2].

Fc Receptor (FcR) 相关产品 (25):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-158316
    BTL-MK Inhibitor
    BTL-MK (Compound 19) 是口服有效的抗过敏剂,通过与抑制性受体 FcγRIIB 结合,抑制肥大细胞脱粒,IC50 为 6.7 μM。BTL-MK BTL-MK 可以改善人肝微粒体的代谢稳定性。BTL-MK 可改善 Ovalbumins (HY-W250978) 诱导的小鼠食物过敏反应。BTL-MK 具有良好的药代动力学特征。
    BTL-MK
  • HY-P991582
    BI-1607 Antagonist
    BI-1607 是一种靶向 CD32b/FcγRIIB 的人源化单克隆抗体。BI-1607 具有拮抗作用,能够阻断 FcγRIIB 对免疫效应细胞的抑制作用。BI-1607 与 Trastuzumab (HY-P9907) 联合使用,可显著抑制 HER2 阳性实体瘤,包括晚期胃癌 (GC) 。
    BI-1607
  • HY-P991225
    BI-1206 Antagonist
    BI-1206 是一种靶向 FcγRIIB (CD32B) 的重组拮抗性人源单克隆抗体。BI-1206 可以阻断 Rituximab (HY-P9913) 本身或与其他药物包括 Ibrutinib (HY-10997),Venetoclax (HY-15531),和 CHOP 联合使用时诱导的 CD20 内化。BI-1206 可以增强或恢复 Rituximab 或其他抗 CD20 单克隆抗体的活性。BI-1206 具有对抗恶性 B 细胞的细胞溶解活性。BI-1206 可用于研究套细胞淋巴瘤 (MCL) 等癌症的研究。
    BI-1206
  • HY-P991502
    Armenian hamster IgG1 kappa, Isotype Control
    Armenian hamster IgG1 kappa, Isotype Control,一种亚美尼亚仓鼠单克隆抗体,是 Armenian hamster IgG1κ 抗体的同型对照。
    Armenian hamster IgG1 kappa, Isotype Control
  • HY-P990290
    Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) Inhibitor
    Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) 是一种小鼠源性 IgG2a κ 型抗体抑制剂,靶向小鼠 CD16/CD32。Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) 是原始 2.4G2 抗体 (HY-P99125) 的嵌合抗体。Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) 包含 LALA-PG 突变区域。Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) 可阻断 CD16 与 FcγRs 的结合。Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) 可用于免疫学和心血管疾病研究。
    Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2)